Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00294996
Other study ID # STM01-102
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received February 17, 2006
Last updated March 30, 2009
Start date January 2006

Study information

Verified date March 2009
Source Sopherion Therapeutics
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of the study is to examine the safety and effectiveness of the drug combination of Myocet, paclitaxel and trastuzumab compared to paclitaxel and trastuzumab without Myocet, as first line treatment for patients with metastatic HER2+ breast cancer.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 363
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Metastatic Her2+ Breast cancer by FISH analysis

- No prior chemotherapy for metastatic disease

- Measurable disease

- normal left ventricular ejection fraction

Exclusion Criteria:

- prior doxorubicin treatment exceeding 300 mg/m2 or epirubicin exceeding 600 mg/m2

- relapse within 12 months of completion of adjuvant trastuzumab, taxane or anthracycline therapy

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Myocet


Locations

Country Name City State
Argentina Centro Oncologico de Excelencia Buenos Aires
Argentina Hospital Enrique Tornú Buenos Aires
Argentina Hospital Interzonal Gral de Agudos " EVITA" Buenos Aires
Argentina Hospital Profesor A. Posadas Buenos Aires
Argentina Santorio Municipal Dr. J. Mendez Buenos Aires
Argentina Unidad Oncologica del Neuquen Neuquen
Argentina CAICI Instituto Santa Fe
Argentina Centro Oncologico Rosario Santa Fe
Argentina ISIS Clinica Especializada Santa Fe
Argentina Ceten Villa Dominico
Canada QEII Health Sciences Centre Halifax Nova Scotia
Canada London Regional Cancer Centre/London Health Science Centre London Ontario
Canada Dr. Leon Richard Oncology Centre Moncton New Brunswick
Canada CHUM Hospital Notre-Dame Montreal Quebec
Canada McGill University Montreal Quebec
Canada The Ottawa Hospital Regional Cancer Center Ottawa Ontario
Canada Hopital du St. Sacrement Quebec
Canada Allan Blair Cancer Centre Regina Saskatchewan
Canada Saskatoon Cancer Centre Saskatoon Saskatchewan
Canada Princess Margaret Hospital Toronto Ontario
Germany U.K Charité, Campus Mitte Berlin
Germany Universitätsklinikum Magdeburg Magdeburg
Germany Gemeinschaftspraxis Gynäkologie & Geburtshilfe Mannheim
Germany Frauenklinik von Roten Kreuz München
Germany Klinikum Offenbach Offenbach
Germany Üniversitäts Klinikum Tübingen Tübingen
Germany Dr. Horst Schmidt Kliniken Wiesbaden
India Gujarat Cancer Research Institute Asarwa Gujarat
India Kidwai Memorial Institute of Oncology Bangalore
India Manipal Hospital Bangalore
India Apollo Specialty Hospitals, Chennai Chennai
India Nizam's Institute of Medical Science Hyderabaad
India SMSMedicalCollegeHospital, Jaipur
India Lakeshore Hospital and Research Centre Ltd Kerala
India Himadri cancer welfare trusr Kolkata
India Orchid Nursing Home, Kolkata
India Ruby Hall Clinic Maharashtra
India Tata Memorial Hospital Maharashtra
India Kasturba Medical College, Mangalore
India Jaslok Hospital and Research Centre Mumbai
India Batra Hospital & Medical Research Center New Delhi
India Indraprastha Apollo Hospitals New Delhi
India Safdarjung Hospital & Vardhaman Mahaveer Medical College New Delhi
India Fortis Hospital Noida
Italy Azienda Ospedialera Pugliese-Ciaccio Catanzaro
Italy Clinica Oncologica Ospedale Chieti
Italy DIMI - Università di Genova Genova
Italy ARNAS CIVICO. Presidio Ospedaliero M. Ascoli Palermo
Italy Oncologia Medica Pavia
Italy Day Hospital Oncologico, Roma
Italy Istituto Clinico Humanitas Rozzano
Poland SP SK nr1 ACK AMG Gdansk
Poland Centrum Onkologii - Instytut Marii Sklodowskiej-Curie Oddzial Gliwice Gliwice
Poland Regionalny Osrodek Onkologiczny Lódz
Poland Samodzielny Publiczny Szpital Lublin
Poland Zaklad Opieki Zdrowotnej MSWiA Olsztyn
Poland Regionalny Szpital Specjalistyczny Swidnica
Poland Szpital Wojewódzki im. Sw. Lukasza Tarnow
Poland Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie Warszawa
Poland Wojskowy Instytut Medyczny Warszawa
Poland SP ZOZ Szpital Wojewódzki Zielona Gora
Portugal nstituto Português de Oncologia Francisco Gentil Lisbon
Russian Federation Non-state Health Care Insitution "N.A. Semashko Central Clinical Hospital #2" of the "Russian Railways" Joint Stock Company Moscow
Russian Federation State Institution "N.N. Blokhin Russian Oncology Scientific Center" of the Russian Academy of Medical Sciences Moscow
Russian Federation State Science Institution "P.A. Hertzen Moscow Oncology Research Institute" of the Federal Agency of Health Care and Social Development Moscow
Russian Federation State Health Care Institution "Regional Clinical Oncology Dispensary" Ryazan
Russian Federation Municipal Health Care Institution of the City of Sochi "Oncology Dispensary" Sochi
Russian Federation St. Petersburg State Health Care Institution "City Clinical Oncology Dispensary" St Petersberg
Russian Federation State Science Institution "Prof. N.N. Petrov Research Institute of Oncology" of the Federal Agency of Health Care and Social Development St Petersberg
Russian Federation Research Institute of Pulmonology affiliated with State Educational Institution "St. Petersburg State Medical University n.a. academician I.P. Pavlov" of the Federal Agency of Health Care and Social Development St. Petersberg
Russian Federation State Health Care Institution "Leningrad Regional Oncology Dispensary" St. Petersburg
Russian Federation State Health Care Institution of the Yaroslavl Region "Yaroslavl Regional Oncology Dispensary" Yaroslavl
Spain Hospital de la Santa Creu i Sant Pau Barcelona
Spain Hospital Universitario Vall d'Hebron Barcelona
Spain Hospital Universitari Arnau de Vilanova de Lleida Lleida
Spain Hospital 12 de Octubre Madrid
Spain Hospital Son Dureta Palma de Mallorca
Spain Hospital Clínico Universitario de Salamanca Salamanca
Spain Hospital Virgen Macarena Sevilla
Spain Hospital Mutua de Terrassa Terrassa
Spain Hospital Clínico Universitario de Valencia Valencia
Spain Hospital General Universitario de Valencia Valencia
Spain Hospital Clínico Universitario Lozano Blesa Zaragoza
United Kingdom Broomfield Hospital Broomfield
United Kingdom Christie Hospital NHS Trust Cardiff
United Kingdom Guy's Hospital London
United Kingdom Royal Free Hospital London
United States University of Colorado Aurora Colorado
United States Vita Hematology Oncology Bethlehem Pennsylvania
United States Aultman Hospital Cancer Center Canton Ohio
United States M. Francisco Gonzalez Columbia South Carolina
United States Hematology Oncology Consultants, Inc. Columbus Ohio
United States John B. Amos Cancer Center Columbus Georgia
United States Northwest Hematology/Oncology Associates Coral Springs Florida
United States Western Maryland Health System Cumberland Maryland
United States Hematology & Oncology Associates of NEPA Dunmore Pennsylvania
United States Brody School of Medicine @ ECU Greenville North Carolina
United States Hutchinson Clinic P.A. Hutchinson Kansas
United States Osceola Cancer Center Kissimmee Florida
United States Tennessee Cancer Specialists Knoxville Tennessee
United States PA Oncology Hematology Asso Philadelphia Pennsylvania
United States UM/Sylvester Cancer Center Plantation Florida
United States Scripps Cancer Center Clinical Research San Diego California
United States Sioux Valley Clinic Sioux Falls South Dakota
United States Clintell, Inc Skokie Illinois

Sponsors (1)

Lead Sponsor Collaborator
Sopherion Therapeutics

Countries where clinical trial is conducted

United States,  Argentina,  Canada,  Germany,  India,  Italy,  Poland,  Portugal,  Russian Federation,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-Free Survival
Secondary Overall Survival
Secondary Safety
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A